FDA Accepts Joenja sNDA for Lower-Weight Children, Grants Priority Review
PHAR is trading near its 52-week low of $9.62 (9.1% above the low) on elevated volume (4.1× avg).
Summary
FDA accepted Pharming's sNDA for lower doses of Joenja in children aged 4+ weighing 13–27 kg with APDS, granted Priority Review, and set a PDUFA target action date of January 30, 2027.
Key Events · Product Development and Regulatory · PHAR
-
FDA Accepts Lower-Dose Joenja sNDA
The FDA accepted Pharming's supplemental New Drug Application for lower doses of Joenja (leniolisib) for children aged 4 years and older weighing between 13 kg and 27 kg with APDS.
-
Priority Review Granted
The application received Priority Review, which the FDA grants to medicines that could offer significant improvements in effectiveness or safety for serious conditions.
-
PDUFA Date Set for January 30, 2027
The FDA assigned a Prescription Drug User Fee Act target action date of January 30, 2027 for the lower-dose sNDA.
-
Expands Pediatric Label Beyond 27 kg
This filing follows the September 2026 approval of Joenja for children aged 4 to 11 weighing at least 27 kg, and would extend treatment to smaller children currently ineligible for Joenja.
Analysis · PHAR · Life Sciences
Pharming's supplemental application to extend Joenja to children weighing 13–27 kg has been accepted with Priority Review, setting a PDUFA date of January 30, 2027. This expands the addressable pediatric population beyond the September 2026 approval for children weighing at least 27 kg, and Priority Review signals the FDA sees the lower-dose filing as potentially offering a significant improvement for a serious condition.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PHAR was trading at $10.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $734.8M. The 52-week trading range was $9.62 to $21.34. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.